Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours
about
Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport functionImaging hemodynamics.Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretationDynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and ExamplesFunctional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI.BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.Modeling the effect of intra-voxel diffusion of contrast agent on the quantitative analysis of dynamic contrast enhanced magnetic resonance imaging.Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in miceTargeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Diagnosis of brain tumors using dynamic contrast-enhanced perfusion imaging with a short acquisition timeHigh-field small animal magnetic resonance oncology studies.Dynamic contrast-enhanced MR microscopy identifies regions of therapeutic response in a preclinical model of colorectal adenocarcinoma.High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI.Dependence of DCE-MRI biomarker values on analysis algorithm.MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft modelRole of vandetanib in the management of medullary thyroid cancerMRI for assessing antivascular cancer treatments.Diagnostic Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Detecting Residual or Recurrent Prostate Cancer After Radical Prostatectomy: A Pooled Analysis of 12 Individual Studies.ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activityEffects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.Molecular MR Imaging ProbesInhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas.Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review.Pharmacokinetic evaluation of axitinib.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.Vandetanib for the treatment of thyroid cancer: an update.Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome.Models and methods for analyzing DCE-MRI: a review.Response-Derived Input Function Estimation for Dynamic Contrast-Enhanced MRI Demonstrated by Anti-DLL4 Treatment in a Murine U87 Xenograft Model.Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT.
P2860
Q28475378-F27AD0A1-385E-4A30-B57C-C29F07285F7AQ30439974-31A4850A-CC75-4F05-B8CE-F47694489EA7Q30575110-4A02B38C-65CB-43E4-AF94-AAE4BA56E871Q30992467-B62222CF-B2A1-4625-9C61-43AD5353EC24Q33510695-B280EF0C-CF40-45DE-9DB8-50EA9266CECCQ33809311-EA8D0983-527C-4168-B105-1975DAD8F808Q34059649-3CF99D9F-6D48-4C6C-8C9A-39219DE2F2FBQ34111200-4789617A-D810-45A3-A1D9-FBC361BEE1E3Q34282239-D55D58B7-19C6-41AD-A3AA-BF88BD8C78CFQ34508475-F0C62DBF-41B0-477A-B0B9-EEDAB1325201Q34633674-D5DA77A8-F0D8-427E-8922-C99CFA372D9DQ34810321-99EB688A-AF07-499A-B9FE-9A1F75944B7EQ35175935-28A63373-8A19-4BB0-A43D-94BC96EA2F78Q35312455-9A09525E-BA82-4395-859E-CA18284D1B7EQ35537599-62030BE6-CBB9-41A1-A6F7-311FA5144751Q35625666-9EF77211-45A6-4187-B220-BA5F7931E4F7Q35711964-CC6E6040-4591-42DB-BC77-A28B9B963943Q35880395-6411FC1C-591D-4A3B-8355-FF7DB611B4A7Q35884666-E58B7F8F-E63C-4008-A764-AC88E050F93BQ35905005-CA21A2A7-EEE2-4876-ACFD-3408D8D7A694Q36063296-7358DA25-9718-4E38-88EA-11506EF925B9Q36146888-BF863007-A091-4BC5-828F-B802454574FCQ36615531-E7F3918E-9021-45F0-89BF-2062E7FEBDFBQ37079267-B02D2F47-A444-4EB7-82CE-9935CE87A7ABQ37228446-6B1C83E6-D7B0-44FE-9EB9-6E3F450063EBQ37328130-68A4FF93-D95C-4462-9BAA-6F376A33A5D5Q37331117-93E494A6-77D3-4318-AD5D-502D79456CB1Q37344824-E3406ECC-7B04-488F-944C-5FD882BB0108Q37418739-5364E66D-F679-427D-A9F0-7FBE0BD1C118Q37461714-F5C59CF6-B92A-41B6-A7A5-C5730309A7ACQ37826430-D7F89D80-242C-4EA4-B1AB-0771874841BCQ37871859-2F82BF35-61A8-42E8-99D2-07B057F131E2Q37976135-1B44A06A-B407-4D22-9609-599770908814Q38168371-A4CC007F-3692-4DE9-B040-AD9296856DB2Q38185691-C1BF1F1E-AD3A-434C-A5DC-BE53C235AD57Q38269850-FA9BBA66-A9C9-4F81-9BA6-CD125E5489B2Q38271116-73330E4D-93CE-4F28-92D5-1711716CBE8FQ38282639-5307F9A7-1467-4B4A-96F6-5EA8D49B7AFCQ38925774-01A85A81-2099-4A6C-825C-3FADDADE062CQ39642439-94349D0C-D80A-4B06-AA8C-D77FE15F1964
P2860
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Use of dynamic contrast-enhanc ...... itor, in PC-3 prostate tumours
@ast
Use of dynamic contrast-enhanc ...... itor, in PC-3 prostate tumours
@en
type
label
Use of dynamic contrast-enhanc ...... itor, in PC-3 prostate tumours
@ast
Use of dynamic contrast-enhanc ...... itor, in PC-3 prostate tumours
@en
prefLabel
Use of dynamic contrast-enhanc ...... itor, in PC-3 prostate tumours
@ast
Use of dynamic contrast-enhanc ...... itor, in PC-3 prostate tumours
@en
P2093
P2860
P356
P1476
Use of dynamic contrast-enhanc ...... itor, in PC-3 prostate tumours
@en
P2093
D Checkley
J J Tessier
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601386
P407
P577
2003-11-01T00:00:00Z